• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.15% Nasdaq Up0.36%

    More On MBX.TO



    News & Info


    Analyst Coverage


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Microbix Biosystems Inc. (MBX.TO)

    0.68 Down 0.03(4.23%) Dec 19, 3:26PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Microbix Biosystems Inc.
    265 Watline Avenue
    Mississauga, ON L4Z 1P3
    Canada - Map
    Phone: 905-361-8910
    Fax: 905-361-8911
    Website: http://www.microbix.com

    Index Membership:N/A
    Full Time Employees:N/A

    Business Summary 

    Microbix Biosystems Inc., a biotechnology company, develops, manufactures, and sells biological products and technologies in North America, Europe, and internationally. The company provides cell culture based infectious disease products; and licenses cell culture based technologies, as well as is involved in the contract development work in microbiology. It also offers infectious disease antigens, such as viral, bacterial, and parasitic products used in various applications, including immunodiagnostic assays; basic and applied research in virology, microbiology, cell biology, molecular biology, immunology, and pathology; as controls and calibrators for a range of medical devices; and for vaccine and antiviral research and development. In addition, the company provides adenovirus vectors, cells, and services to biopharmaceutical and biotechnology researchers and companies. The company develops various biological technologies, including VIRUSMAX, a vaccine manufacturing technology; LumiSort, a semen sexing technology; and Kinlytic, a thrombolytic drug. It serves medical diagnostic and biotechnology industries. The company was founded in 1988 and is headquartered in Mississauga, Canada.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Microbix Biosystems Inc.

    Key Executives 
    Mr. William J. Gastle ,
    Founder, Exec. Chairman and Member of HR & Compensation Committee
    Mr. Vaughn C. Embro-Pantalony ,
    Chief Exec. Officer, Pres and Director
    Mr. Charles S. Wallace ,
    Chief Financial Officer
    Mr. Philip Casselli ,
    Sr. VP of Sales & Bus. Devel.
    Mr. Kevin J. Cassidy ,
    VP of Biotherapeutics
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in CAD.